SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Lyka Labs Ltd

BSE: 500259 NSE: LYKALABS ISIN: INE933A01014
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Lyka Labs Ltd belong to?
Lyka Labs Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Lyka Labs Ltd a good quality company?
Lyka Labs Ltd is a weak quality company, based on a inconsistent 10 year financial track record.
Q.3 Is Lyka Labs Ltd undervalued or overvalued?
Lyka Labs Ltd appears Somewhat Undervalued, as its key valuation ratios are below with their past averages.
Q.4 Is Lyka Labs Ltd a good buy now?
Lyka Labs Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Lyka Labs Ltd?
Lyka Labs Ltd revenue growth is 26.6% for FY-2025 , which is below its 5 year CAGR of 27% , indicating slower growth.
Q.2 Gross Profit margin of Lyka Labs Ltd?
Lyka Labs Ltd Gross profit margin which is the profit after deduction of direct costs, is 13.3% for FY-2025 , which is above its 5 year median of 10.7% , indicating increasing margins.
Q.3 Operating Profit Margin of Lyka Labs Ltd?
Lyka Labs Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 13.28% for FY-2025 , which is below its 5 year median of 19.36% indicating decreasing margins.
Q.4 Net Profit Margin of Lyka Labs Ltd?
Lyka Labs Ltd Net Profit Margin is 6.11% for FY-2025 , is above with its 5 year median of -2.13%, indicating increasing margins.
Current Level Historic Median
Gross Profit Margin 13.3 10.7
Operating Profit Margin 13.28 19.36
Net Profit Margin 6.11 -2.13
Q.5 Return on Asset of Lyka Labs Ltd?
Lyka Labs Ltd Return on Asset is 4.2%, which is above its 5 year historical median of -1.24%, indicating improved asset utilization efficiency.
Q.6 Return on Equity (ROE) of Lyka Labs Ltd?
Lyka Labs Ltd Return on equity is 7.31% for FY-2025 , which is above its historical median of -3.04%, indicating the business is making better use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Lyka Labs Ltd?
Lyka Labs Ltd Return on capital employed is 8.38% for FY-2025 , which is below its estimated weighted average cost of capital(WACC) 14%, indicating value preservation.
Q.8 Cash conversion cycle of Lyka Labs Ltd?
Lyka Labs Ltd Cash conversion cycle is 79 days, above its historical median of 65 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.69 0.58
ROE 7.31 -3.04
ROCE 8.38 4.45
Cash Conversion Cycle 79 days 65 days
Q.9 Debt to Equity ratio of Lyka Labs Ltd?
Lyka Labs Ltd Debt-to-Equity ratio is 0.28 , which is above with the industry average of 0.15 , indicating higher debt levels in the industry.
Q.10 Debt to cash flow from operations of Lyka Labs Ltd?
Lyka Labs Ltd Debt to cash flow from operations is 11.61 , which is at a unhealthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Lyka Labs Ltd?
Promoters hold 58.16% of the Lyka Labs Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Lyka Labs Ltd vs industry peers?
Lyka Labs Ltd revenue CAGR is 27.02% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 134.7 137.1
Gross Profit 18 15.1
Operating Profit 18 16
Net Profit 8 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.69 0.8
ROE 7.31 8.91
ROCE 8.38 11.59
Cash Conversion Cycle (days) 79.1 76

Valuation & price assessment

Q.1 Stock return of Lyka Labs Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of -3.7% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price -3.7% 17.5% -19.1% -45.3%
Q.3 Valuation ratios of Lyka Labs Ltd vs historical?
The current P/E is similar that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings - 0.00 40.28
Price to Book 1.55 4.57 2.77
Price to Sales 1.67 1.40 2.65
EV to EBITDA 24.99 127.99 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×